“Clinical development involving rare diseases poses a unique set of medical, scientific, and operational challenges. PRA understands these challenges and the critical success factors necessary to develop drugs for rare disease patients. It’s not a cookie-cutter formula, but rather a nimble approach that embraces the flexibility, creativity, and innovation needed to succeed in this arena. Since 2010, we have managed over 90 Phase I-IV rare disease trials in 10 therapeutic areas and contributed to the successful market approval of 14 drugs.”
Find out more about:
- Clinical Development at PRA Health Science
- The importance of Advocacy Group Engagement
- PRA’s Expertise and Experience
We are thrilled to announce that PRA Health Sciences are joining us as a sponsor at this year’s World Orphan Drug Congress USA 2016. Register today to meet them in D.C. on April 20-22.